Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017.
HIV
chemsex
men who have sex with men
recreational drug use
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
accepted:
10
10
2019
pubmed:
19
12
2019
medline:
28
9
2021
entrez:
19
12
2019
Statut:
ppublish
Résumé
Chemsex refers to the use of sex-enhancing drugs among men who have sex with men (MSM) in combination with specific sexual and social behaviours. Longitudinal data on this development and the associated health risks are scarce. Data on all recreational drugs reported in the Swiss HIV Cohort Study (SHCS) from 2007 to 2017 were collected. Drug use was analysed longitudinally for all drug classes. In addition, potential associations between patient characteristics and the consumption of methamphetamine, γ-hydroxybutric acid/γ-butyrolactone (GHB/GBL), 3,4-methylenedioxymethamphetamine (MDMA/XTC), cocaine and amphetamine were analysed. We analysed 166 167 follow-up entries for 12 527 SHCS participants, including 7101 free text field entries containing information about recreational drugs other than cannabis, cocaine and heroin. Overall, we observed a stable percentage (9.0%) of recreational drug use (excluding cannabis, amyl nitrite and prescription drugs). For MSM, however, there was an increase in overall drug use from 8.8% in 2007 to 13.8% in 2017, with particularly large increases for methamphetamine (from 0.2 to 2.4%; P < 0.001) and GHB/GBL (from 1.0 to 3.4%; P < 0.001). The use of each of the potentially sex-enhancing drugs methamphetamine, GHB/GBL, cocaine, XTC/MDMA and amphetamine was significantly associated with condomless sex with nonsteady partners, and higher prevalences of depression, syphilis and hepatitis C. The significant increase in the use of chemsex drugs among MSM in the SHCS and the strong association with coinfections and depression highlights the need for harm reduction programmes tailored to MSM. According to our results, improving knowledge about recreational drugs is important for all health care professionals working with people living with HIV.
Substances chimiques
Illicit Drugs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
228-239Investigateurs
A Anagnostopoulos
(A)
M Battegay
(M)
H C Bucher
(HC)
A Calmy
(A)
M Cavassini
(M)
A Ciuffi
(A)
G Dollenmaier
(G)
M Egger
(M)
L Elzi
(L)
J Fellay
(J)
H Furrer
(H)
C A Fux
(CA)
D Haerry
(D)
B Hasse
(B)
H H Hirsch
(HH)
M Hoffmann
(M)
I Hösli
(I)
M Huber
(M)
C Kahlert
(C)
L Kaiser
(L)
O Keiser
(O)
T Klimkait
(T)
H Kovari
(H)
B Ledergerber
(B)
G Martinetti
(G)
B Martinez de Tejada
(B)
C Marzolini
(C)
K J Metzner
(KJ)
N Müller
(N)
P Paioni
(P)
G Pantaleo
(G)
M Perreau
(M)
C Rudin
(C)
A U Scherrer
(AU)
P Schmid
(P)
R Speck
(R)
P Tarr
(P)
A Trkola
(A)
P Vernazza
(P)
G Wandeler
(G)
R Weber
(R)
S Yerly
(S)
Informations de copyright
© 2019 British HIV Association.
Références
Hegazi A, Lee MJ, Whittaker W et al. Chemsex and the city: sexualised substance use in gay bisexual and other men who have sex with men attending sexual health clinics. Int J STD AIDS 2017; 28: 362-366.
Bourne A, Reid D, Hickson F, Torres-Rueda S, Weatherburn P. Illicit drug use in sexual settings ('chemsex') and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study. Sex Transm Infect 2015; 91: 564-568.
Schmidt AJ, Bourne A, Weatherburn P, Reid D, Marcus U, Hickson F. Illicit drug use among gay and bisexual men in 44 cities: findings from the European MSM Internet Survey (EMIS). Int J Drug Policy 2016; 38: 4-12.
Zobel F, Schneider C, Marthaler M. Neue Tendenzen im Drogenbereich (NTD) Methamphetamin in der Schweiz. Lausanne, Sucht Schweiz, 2015.
Daskalopoulou M, Rodger A, Phillips AN et al. Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. Lancet HIV 2014; 1: e22-e31.
Ireland G, Higgins S, Goorney B et al. Evaluation of hepatitis C testing in men who have sex with men, and associated risk behaviours, in Manchester, UK. Sex Transm Infect 2017; 93: 404-409.
Folch C, Fernandez-Davila P, Ferrer L, Soriano R, Diez M, Casabona J. High prevalence of drug consumption and sexual risk behaviors in men who have sex with men. Med Clin 2015; 145: 102-107.
The EMIS network: EMIS 2010: the European men-who-have-sex-with-men internet survey. Findings from 38 countries. European Centre for Disease Prevention and Control, 2013. 2013.
Beymer MR, Weiss RE, Bolan RK et al. Sex on-demand: geosocial networking phone apps and risk of sexually transmitted infections among a cross-sectional sample of men who have sex with men in Los Angeles county. Sex Transm Infect 2014; 90: 567-572.
Chew Ng RA, Samuel MC, Lo T et al. Sex, drugs (methamphetamines), and the Internet: increasing syphilis among men who have sex with men in California, 2004-2008. Am J Public Health 2013; 103: 1450-1456.
Winetrobe H, Rice E, Bauermeister J, Petering R, Holloway IW. Associations of unprotected anal intercourse with Grindr-met partners among Grindr-using young men who have sex with men in Los Angeles. AIDS Care 2014; 26: 1303-1308.
Bundesamt für Gesundheit. HIV, syphilis, gonorrhoe und chlamydiose in der Schweiz im Jahr 2016: eine epidemiologische Übersicht. BAG-Bulletin 2017; 43: 29.
Wandeler G, Schlauri M, Jaquier ME et al. Incident hepatitis C virus infections in the Swiss HIV cohort study: changes in treatment uptake and outcomes between 1991 and 2013. Open Forum Infect Dis 2015; 2: ofv026.
Schoeni-Affolter F, Ledergerber B, Rickenbach M et al. Cohort profile: the Swiss HIV cohort study. Int J Epidemiol 2010; 39: 1179-1189.
van Sighem A, Vidondo B, Glass TR et al. Resurgence of HIV infection among men who have sex with men in Switzerland: mathematical modelling study. PLoS ONE 2012; 7: e44819.
Glass TR, Sterne JA, Schneider MP et al. Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. AIDS 2015; 29: 2195-2200.
Anagnostopoulos A, Ledergerber B, Jaccard R et al. Frequency of and risk factors for depression among participants in the Swiss HIV Cohort Study (SHCS). PLoS ONE 2015; 10: e0140943.
Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010; 376: 1558-1565.
R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria, R Foundation for Statistical Computing, 2008. http://www.R-project.org (accessed 01 March 2019).
Braun DL, Hampel B, Kouyos R et al. High cure rates with Grazoprevir-elbasvir with or without ribavirin guided by genotypic resistance testing among human immunodeficiency virus/hepatitis C virus-coinfected men who have sex with men. Clin Infect Dis 2018; 68: 569-576.
Millar BM, Starks TJ, Grov C, Parsons JT. Sexual Risk-Taking in HIV-Negative Gay and Bisexual Men Increases with Depression: Results from a U.S. National Study. AIDS Behav 2017; 21: 1665-1675.
Giraudon I, Schmidt AJ, Mohammed H. Surveillance of sexualised drug use - the challenges and the opportunities. Int J Drug Policy 2018; 55: 149-154.
Khan R, Khazaal Y, Thorens G, Zullino D, Uchtenhagen A. Understanding Swiss drug policy change and the introduction of heroin maintenance treatment. Eur Addict Res 2014; 20: 200-207.
Hungerbuehler I, Buecheli A, Schaub M. Drug checking: a prevention measure for a heterogeneous group with high consumption frequency and polydrug use - evaluation of Zurich's drug checking services. Harm Reduct J 2011; 8: 16.
Chinet L, Stephan P, Zobel F, Halfon O. Party drug use in techno nights: a field survey among French-speaking Swiss attendees. Pharmacol Biochem Behav 2007; 86: 284-289.
Somaini B, Grob P. How and why AIDS changed drug policy in Switzerland. J Public Health Policy 2012; 33: 317-324.